与礼来(LLY.US)签署并购协议后 Sigilon Therapeutics(SGTX.US)周四暴涨438%

智通财经2023-06-30

智通财经APP获悉，在礼来(LLY.US)同意收购美国生物技术公司Sigilon Therapeutics(SGTX.US)后，该公司股价周四收涨438%，至21.15美元。据Sigilon最新的代理文件显示，Noubar Afeyan的风险投资公司Flagship Pioneering旗下的基金持有该公司31.9%的股份。不仅如此，如果Sigilon达到某些基准，Afeyan可能会获得更高的回报...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2347036698?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-06-30 07:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2347036698","market":"us","top_or_hot":-1,"title":"与礼来(LLY.US)签署并购协议后 Sigilon Therapeutics(SGTX.US)周四暴涨438%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，在礼来(LLY.US)同意收购美国生物技术公司Sigilon Therapeutics(SGTX.US)后，该公司股价周四收涨438%，至21.15美元。据Sigilon最新的代理文件显示，Noubar Afeyan的风险投资公司Flagship Pioneering旗下的基金持有该公司31.9%的股份。不仅如此，如果Sigilon达到某些基准，Afeyan可能会获得更高的回报...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/953093.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>与礼来(LLY.US)签署并购协议后 Sigilon Therapeutics(SGTX.US)周四暴涨438%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n与礼来(LLY.US)签署并购协议后 Sigilon Therapeutics(SGTX.US)周四暴涨438%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-30 07:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/953093.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，在礼来(LLY.US)同意收购美国生物技术公司Sigilon Therapeutics(SGTX.US)后，该公司股价周四收涨438%，至21.15美元。据Sigilon最新的代理文件显示，Noubar Afeyan的风险投资公司Flagship Pioneering旗下的基金持有该公司31.9%的股份。不仅如此，如果Sigilon达到某些基准，Afeyan可能会获得更高的回报...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/953093.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/953093.html","article_id":"2347036698","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2347036698","pubTimestamp":1688082677,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，在礼来同意收购美国生物技术公司Sigilon Therapeutics后，该公司股价周四收涨438%，至21.15美元。据Sigilon最新的代理文件显示，Noubar Afeyan的风险投资公司Flagship Pioneering旗下的基金持有该公司31.9%的股份。不仅如此，如果Sigilon达到某些基准，Afeyan可能会获得更高的回报。但可以肯定的是，Sigilon必须克服重重障碍才能获得全额价格。交易完成后，Sigilon股东将获得总计3460万美元，相当于每股14.92美元。此外，就在上个月，Sigilon还面临着被摘牌的风险，因为其股价太低了。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LLY":"礼来","BK4139":"生物科技","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SGTX":"Sigilon Therapeutics, Inc.","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4588":"碎股","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Sigilon Therapeutics (SGTX.US) surged 438% Thursday after signing a merger agreement with LLY.US","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGTX":1,"LLY":1},"content_text":"智通财经APP获悉，在礼来(LLY.US)同意收购美国生物技术公司Sigilon Therapeutics(SGTX.US)后，该公司股价周四收涨438%，至21.15美元。据Sigilon最新的代理文件显示，Noubar Afeyan的风险投资公司Flagship Pioneering旗下的基金持有该公司31.9%的股份。不仅如此，如果Sigilon达到某些基准，Afeyan可能会获得更高的回报。如果所有条件都得到满足，礼来的出价将升至每股126.56美元，而他的公司的意外之财将达到1.01亿美元。但可以肯定的是，Sigilon必须克服重重障碍才能获得全额价格。交易完成后，Sigilon股东将获得总计3460万美元，相当于每股14.92美元。为了获得剩余的资金，Sigilon的产品——针对糖尿病等疾病的非病毒工程细胞疗法——将需要完成三个步骤，最终和最大的支出取决于监管部门对特定产品的批准。该公司在周四的一份文件中表示，“无法保证会支付任何款项”。此外，就在上个月，Sigilon还面临着被摘牌的风险，因为其股价太低了。该公司进行了1比13的反向拆股，使其股价足以满足继续在纳斯达克上市的最低价格要求。对此，BTIG分析师Thomas Shrader表示，第一次支付的条件很有可能得到满足，而他认为第二次支付的可能性“不会超过50%”。但该股周四的收盘价高于礼来最初支付的14.92美元，表明投资者相信至少有部分障碍会得到解决。值得一提的是，Afeyan曾在支持Moderna(MRNA.US)后成为了亿万富翁，该公司是一家黑马生物技术公司，因新冠疫苗而家喻户晓。和Moderna一样，Sigilon总部位于马萨诸塞州的剑桥。该公司还有一位共同创始人:麻省理工学院教授Robert Langer，他也通过这家疫苗制造商成为了亿万富翁。根据Afeyan的简历，他是一名生化工程师，拥有100多项专利，并参与了70多家生命科学行业的创业公司。他出生在黎巴嫩，1975年全家为了逃离内战搬到加拿大。他来到美国就读麻省理工学院研究生院，此后一直住在波士顿地区。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2347036698"}